用户名: 密   码:
注册 | 忘记密码?
专利信息
查询条件 展开筛选条件
  • [药品] 包含 'Muromonab'
排序 翻到页码
标题标题2专利权人发明人附图摘要摘要2优先权号IPC专利类型
首页1尾页9 条记录, 当前第1/1页。
公开号 公开日 申请号 申请日
1. US2014023593A1 2014/1/23 US201313940608 2013/7/12
专利标题:IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 法律状态
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the s...


2. NZ585702A 2013/8/30 NZ20080585702 2008/11/28
专利标题:PROTEIN FORMULATIONS AND METHODS OF MAKING SAME 法律状态
专利权人ABBOTT LAB;
585702 Disclosed herein are aqueous formulations comprising water and at least about 20 mg/mL of an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, has a hydrodynamic diameter (Dh) which is at least about 50% less than the Dh of the antibody or had a hydrodynamic diameters of less than about 4 nm, or antigen-binding fragment thereof, in a buffered solution at the same concentration, and the antibody, or antigen-binding fragment thereof, h...


3. EP2410334A1 2012/1/25 EP20110185960 2008/2/15
专利标题:T-lymphocyte mitogen for use in a skin test 法律状态
The T lymphocyte is muromonab-CD3 for testing the effect of immunotherapy on a cancer patient in a skin test


4. US2010047182A1 2010/2/25 US20080527288 2008/2/15
专利标题:IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 法律状态
专利权人
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the s...


5. MX2009008690A 2009/9/4 MX20090008690 2009/8/13
专利标题:IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS. 法律状态
专利权人IRX THERAPEUTICS INC [US];
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab- CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the ...


6. WO2008101154A2 2008/8/21 WO2008US54070 2008/2/15
专利标题:IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 法律状态
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab- CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the ...


7. CA2715529A1 2008/8/21 CA20082715529 2008/2/15
专利标题:IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 法律状态
专利权人IRX THERAPEUTICS INC [US];
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab- CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the ...


8. ES2295495T3 2008/4/16 ES20030024332T 2000/11/23
专利标题:Composiciones que contienen derivados de pirrolo (1,3-d)pirimidina. 法律状态
专利权人Pfizer Products Inc.;
Una combinación que comprende uno o más agentes antiinflamatorios seleccionados del grupo que está constituido por ciclosporina A rapamicina tacrolimus leflunomida deoxispergualina micofenolato azatioprina daclizumab muromonab-CD3 (OKT3) globulina antitimocito (AtGam) aspirina acetaminofeno ibuprofeno naproxeno piroxicam prednisolona y dexametasona y un compuesto de la fórmula o la sal farmacéuticamente aceptable de la misma en la que R1 es un grupo de la fórmula en la que y es 0 1 ó 2; R4 se se...


9. US2007154399A1 2007/7/5 US20070706946 2007/2/15
专利标题:Immunotherapy for immune suppressed patients 法律状态
专利权人
A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the s...



首页1尾页9 条记录, 当前第1/1页。

下载范围

下载第 条记录。

下载内容

题录信息 专利全文